- Home
- RMMZ vs AGEN Comparison
RMMZ vs AGEN Comparison
Compare RMMZ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMMZ | AGEN |
|---|---|---|
| Founded | 2022 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | RMMZ | AGEN |
|---|---|---|
| Price | $14.52 | $3.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 25.6K | ★ 639.2K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | ★ $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.92 | $1.38 |
| 52 Week High | $16.99 | $7.34 |
Technical Indicators
Market Signals| Indicator | RMMZ | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 26.40 |
| Support Level | $14.65 | $3.01 |
| Resistance Level | $14.83 | $4.00 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 21.69 | 11.26 |
Price Performance
Historical ComparisonAbout RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).